Lidco Share Discussion Threads

[microscope] 25/8/2020 14:24

Thanks for some genuinely helpful replies. Lots to reflect on there.Market cap about 23 million at 9p if my maths is right, plus I suppose whatever options warrants etc there are.Not sure what to make of low take up levels, can see what both of you are saying on that. Also interesting about the first and second quarter divergence. They had mentioned that May had seen a return to more normal demand so maybe that has continued.Cash improvement and no debt are obvious positives.On the one hand the return to a surge in delayed treatments should help, on the other a second wave - let's hope not though! - might see another spike in demand but further cancelled operations.I'd think that institutions would want to see some progress to profit before long on the back of recent events. The company has been around a long time now.Much to mull over and I feel I need to do more forensic researchThanks again for the constructive replies.

[multibagger] 25/8/2020 09:00

There is more growth to come, but may not be at the pace the market is hoping for. Anyone investing, as opposed to trading needs to have a multi-year time frame for this to come really good. The signs are there IMHO.

A takeover is one of the key events that will unlock the real value in due course - I am pretty confident it will happen eventually. Patience, as is often the case in investing, is key !

Let's hope we see some Director buys in the near future :)

Good luck all :)

[amt] 25/8/2020 07:30

Initially looks great but when you compare Q2 to Q1 there has been a very marked slowdown and not much cash generated so if Q1 was a one off then share price up with events.

[vega44] 24/8/2020 23:01

Microscope, the only move on the profit front has been to take consensus forecast (Just) into positive territory. The management are focused on driving growth (especially in US and internationally) and I suspect would rather have flexibility to invest in resources to deliver growth without being constrained by market expectations for a meaningful profit.

The gross margins robust so growing revenues should quickly translate into profits in future years.

[hatfullofsky] 24/8/2020 22:49

£1.8m cash inflow is the main take away for me. Not very impressive HUP take up considering the units sold. Maybe I'll add more on the inevitable pull back. Took a small position on the news today

[microscope] 24/8/2020 22:17

All very good, I'm impressed by the update, despite my previous doubts, at least as far as it goes.The only word missing seems to be 'profit'. After all this bullish news, you'd like to think that's the least they could achieve. Perhaps someone who has followed the company longer than myself can clarify?And maybe that goes some way to explaining some hefty sells today.Interested, but still concerned.

[noirua] 24/8/2020 17:40

In H1, total revenues (including third party products) increased by 75% to GBP6.2m (2019: GBP3.5m) with LiDCO product revenues up 83% to GBP6.1m (2019: GBP3.3m).

LiDCO achieved net positive cash inflow of GBP1.8m in H1 (2019: GBP0.5m net outflow).

The Company had GBP3.1m of cash as at 31 July 2020 and has no borrowings.

In the period, HUP revenues increased by 83% to GBP1.5m (2019: GBP0.8m).

Total LiDCO product recurring revenue in H1 was up 12% to GBP2.8m (2019: GBP2.5m).

Geographically, LiDCO product sales grew by 157% in H1 in the UK to GBP4.1m (2019: GBP1.6m). UK hospitals invested in growing their critical care provision by acquiring new monitors to meet anticipated needs.

Distribution markets also grew, by 41% to GBP1.2m (2019: GBP0.8m), with the greatest demand coming from Asia.

During H1, the Company sold 230 monitors compared with 111 units in H1 2019. A number of these monitors were sold with HUP licences, and, as of the 31 July 2020, the global installed base of HUP monitors with annual licences was 327 units (31 July 2019: 216 units).

[multibagger] 24/8/2020 09:49

Surprisingly muted positive response in the share price - maybe market sees this as an one-off set of results directly related to Covid pandemic - which is understandable, however, I see this is differently and think that our prospects have improved tremendously.

[tez123] 24/8/2020 08:49

Record first half performance with LiDCO product revenue up by 83%

[multibagger] 24/8/2020 07:57

Given the recent interest in any listed company healthcare related, I guess we could see some momentum traders arrive. LID is pretty tightly held, so the buying over the last week or so with an increase in share price could have been a sign of good things to come !

Let's see what the day brings, but I expect a fair bit of interest ;)

Good luck all !

[inntolife] 24/8/2020 07:17

What a great thing to read when you wake up :) :)

[multibagger] 24/8/2020 07:13

An exceptional financial performance in these challenging times....and also the pride of owning a tiny fraction of a business that genuinely makes a difference to people's lives !!

Well done to Matt and the team ! I wouldn't be surprised to see a share price spike by about 2- 2.5p today, or even more, given it is pretty tightly held :)

Mon, 24th Aug 2020 07:00

RNS Number : 8874W
LiDCO Group Plc
24 August 2020

LiDCO Group Plc

("LiDCO" or the "Company")



Trading update

Record first half performance with LiDCO product revenue up by 83%



LiDCO (AIM: LID), the hemodynamic monitoring company, provides the following pre-close trading update for the six months ended 31 July 2020 ("H1"), ahead of its interim results which are expected to be announced on 13 October 2020.



LiDCO continues to support healthcare providers to improve patient outcomes while reducing the cost of care, and in H1 successfully responded to exceptional demand related to the COVID-19 pandemic to achieve a record first half performance.



International experts treating COVID-19 patients have concluded that hemodynamic optimisation plays a major role in the management of the complex interaction of respiratory and cardiovascular factors. LiDCO provides a market leading solution, via either the arterial line or non-invasively, to support the diagnostic and therapy-guiding functional hemodynamic tests as recommended by COVID-19 frontline experts and global guidelines.



In H1, total revenues (including third party products) increased by 75% to £6.2m (2019: £3.5m) with LiDCO product revenues up 83% to £6.1m (2019: £3.3m). This exceptionally strong sales growth was due to increased demand for advanced hemodynamic monitors as healthcare providers expanded critical care services to deal with the COVID-19 pandemic, primarily in the UK where LiDCO is market leader.



As a result of the strong top line growth, LiDCO achieved net positive cash inflow of £1.8m in H1 (2019: £0.5m net outflow). The Company had £3.1m of cash as at 31 July 2020 and has no borrowings. Given the strong cash inflow in H1, the Board decided not to continue to take advantage of the UK Government's option to defer VAT payments and brought these payments up to date by 31 July 2020.



As widely reported, there has been a significant postponement in the number of elective surgery procedures during the pandemic. Over the last three years, the Company's key commercial strategy has been to sign up customers for its Software as a Service (SaaS) HUP business model, in which customers pay an annual license fee that is independent of the number of patients treated. HUP customers continue to benefit from this model by not having to pay any extra costs to redeploy LiDCO haemodynamic monitors from use in elective surgeries to providing critical care to COVID-19 patients. In parallel, the Company continues to benefit from the predictable, contracted HUP revenue stream, as well as additional demand from customers taking out new HUP contracts. In the period, HUP revenues increased by 83% to £1.5m (2019: £0.8m). Where customers remained on the pay per patient model, the postponement of elective surgeries led to a reduction in consumable sales by around one fifth compared to H1 2019, but the additional HUP revenues more than offset this reduction. Total LiDCO product recurring revenue in H1 was up 12% to £2.8m (2019: £2.5m).



Geographically, LiDCO product sales grew by 157% in H1 in the UK to £4.1m (2019: £1.6m). UK hospitals invested in growing their critical care provision by acquiring new monitors to meet anticipated needs. Distribution markets also grew, by 41% to £1.2m (2019: £0.8m), with the greatest demand coming from Asia. In the USA, hospitals were focussed on preparing for or dealing with COVID-19, which suppressed capital sales and the finalisation of a number of potential new HUP contracts, although recurring revenues grew slightly compared with the first half of last year. This increase was driven by the carry-through from strong growth in HUP contracts during the prior year, which offset declines in per patient disposables due to the reduced number of elective surgeries in H1.



Around the globe, the Group is actively supporting healthcare providers managing many different stages of the COVID-19 pandemic, including those preparing for a second wave. In the USA, the world's largest healthcare market, elective surgeries started to recommence during Q2 and LiDCO's commercial personnel were able to resume visits to some customers. Further local lockdowns have, however, limited efforts to close the pipeline of new HUP opportunities, which are now targeted to close in H2.



During H1, the Company sold 230 monitors compared with 111 units in H1 2019. A number of these monitors were sold with HUP licences, and, as of the 31 July 2020, the global installed base of HUP monitors with annual licences was 327 units (31 July 2019: 216 units).



Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: "I am incredibly proud of how the entire team has been able to respond quickly to the needs of our customers during these challenging times and ensure that LiDCO plays its part in supporting hospitals in treating COVID-19. The strong start in H1 combined with the forward visibility of HUP revenues and enlarged installed base, gives the Board significant confidence as we look forward."

[effortless cool] 20/8/2020 18:18

LID finally coming off the ventilator?

[buywell3] 10/8/2020 04:39

POST REMOVED

[buywell3] 08/8/2020 23:03

POST REMOVED

[nobbygnome] 20/7/2020 22:09

LOL. And you need to learn some humility and not be a troll. I will be the nicest person to you ever if you do that!

[buywell3] 20/7/2020 22:07

POST REMOVED

[nobbygnome] 20/7/2020 21:58

And now effectively buywell I have 100k shares for free so even you can work out I can't lose now!

[nobbygnome] 20/7/2020 21:49

It will be at least £300k shortly. Watch and learn buywell...

[buywell3] 20/7/2020 21:47

POST REMOVED

[nobbygnome] 20/7/2020 16:54

Buywell did you pick out SNG in your fantastic quality research? No thought not. So just the £150k (mostly on paper) profit for me today! Yes really, as has been well documented on the SNG threads. The sort of money you can only dream of I suspect....

And mark my words OPTI, TLY and SBTX will also show astonishing games over the next year or so although maybe not quite as high as SNG!

[myosite] 19/7/2020 20:52

Michael have you ever been to Pizza Express in Woking?